This product should be further diluted in an intermediate blending step prior to mixing in the final feed. 1. Complete Type C Medicated Feed a.Intermediate blending: Mix 1 part of Bovatec 91 Type A Medicated Article with 17 parts of finely ground non-medicated feedstuffs to provide an intermediate preblend containing 5 grams of lasalocid per pound. b. Using the 5 g/lb intermediate preblend, the following table wou...
www.pahc.com
www.fda.gov/reportanimalaeBovatec® 91
lasalocid sodium
Type A medicated article
For further manufacturing only
Net Wt 50 LB (22.68 kg)
Each pound contains 90.7 grams (20%) of lasalocid sodium in a carrier suitable for incorporation in feed.
This product should be further diluted in an intermediate blending step prior to mixing in the final feed.
1. Complete Type C Medicated Feed
a.Intermediate blending: Mix 1 part of Bovatec 91 Type A Medicated Article with 17 parts of finely ground non-medicated feedstuffs to provide
an intermediate preblend containing 5 grams of lasalocid per pound.
b. Using the 5 g/lb intermediate preblend, the following table would apply to the manufacture of complete Type C medicated feed:
| Intended lasalocid sodium concentration in the complete Type C medicated feed | Add the following amounts of 5 grams per pound intermediate preblend per ton of complete Type C medicated feed mixed: | |
|---|---|---|
| grams/ton | mg/lb | lbs/ton |
| 10 | 5 | 2 |
| 15 | 7.5 | 3 |
| 30* | 15 | 6 |
* Maximum approved concentration for complete Type C medicated feeds for growing beef steers and heifers fed in confinement for slaughter and sheep
maintained in confinement.
c. Using the 5 g/lb intermediate preblend, the following table would apply to the manufacture of other complete Type C medicated feeds and supplements:
| Daily feeding rate | Desired daily lasalocid sodium intake | Add the following amounts of 5 grams per pound intermediate preblend per ton of Type C medicated feed or supplement mixed: | Lasalocid sodium will be present in the Type C medicated feed or supplement at the following concentration: |
|---|---|---|---|
| lbs/head/day | mg/head/day | lbs/ton | grams/ton |
| 1 | 60 | 24 | 120 |
| 200 | 80 | 400 | |
| 300 | 120 | 600 | |
| 2 | 60 | 12 | 60 |
| 200 | 40 | 200 | |
| 300 | 60 | 300 | |
| 3 | 60 | 8 | 40 |
| 200 | 26.7 | 133.5 | |
| 300 | 40 | 200 |
2. Dry Type C Medicated Feed Supplement
a. Intermediate blending: Mix 1 part Bovatec 91 Type A Medicated Article with 3.5 parts of finely ground non-medicated feedstuffs to provide an
intermediate preblend containing 20 grams of lasalocid per pound. For example, mix one 50 lb bag of Bovatec 91 Type A Medicated Article
with 175 lbs of non-medicated feedstuffs.
b. Using the 20 g/lb intermediate preblend, the following table would apply to the manufacture of dry Type C medicated feed supplements:
| Intended lasalocid sodium concentration in the Type C medicated feed supplement | Add the following amounts of 20 grams per pound intermediate preblend per ton of Type C medicated feed supplement mixed: | |
|---|---|---|
| grams/ton | mg/lb | lbs/ton |
| 400 | 200 | 20 |
| 600 | 300 | 30 |
| 1000 | 500 | 50 |
| 1440 | 720 | 72 |
| 1600 | 800 | 80 |
c. Thoroughly mix Type C medicated feed supplement with sufficient non-medicated feedstuffs in accordance with the feeding rates listed in the
use directions below.
3. Type C Liquid Medicated Feed Supplement Intended for Addition to Dry Feeds
a. Type C liquid medicated feed supplements with suspending agent(s) should be in a pH range of 4-8 and maintain physical stability for up to
three months with a viscosity not less than 300 cps.
b. Conventional liquid supplements should be in a pH range of 4-8.
For liquid feeds stored in recirculating tank systems: Recirculate immediately prior to use for no less than 10 minutes,
moving not less than 1 percent of the tank contents per minute from the bottom of the tank to the top. Recirculate daily as
described even when not used.
For liquid feeds stored in mechanical, air, or other agitation-type tank systems: Agitate immediately prior to use for not less than
10 minutes, creating a turbulence at the bottom of the tank that is visible at the top. Agitate daily as described even when not used.
| Species | Dose | Indications for use |
|---|---|---|
| Growing beef steers and heifers fed in confinement for slaughter | 10-30 grams lasalocid sodium per ton of total ration (90% dry matter) | For improved feed efficiency: Feed as the sole ration to provide 100 to 360 mg lasalocid sodium per head per day. |
| 25-30 grams lasalocid sodium per ton of total ration (90% dry matter) | For increased rate of weight gain and improved feed efficiency: Feed as the sole ration to provide 250 to 360 mg lasalocid sodium per head per day. | |
| Growing beef steers and heifers on pasture (stocker, feeder, and slaughter) and replacement beef and dairy heifers | 60-300 mg lasalocid sodium per head/day | For increased rate of weight gain. The drug must be contained in at least 1 pound of feed and fed continuously on a daily basis. |
| 60-300 mg lasalocid sodium per head/day | For increased rate of weight gain: Feed on a free-choice basis. Intakes of lasalocid sodium greater than 200 mg per head per day have not been shown to be more effective than 200 mg per head per day. Type C free-choice medicated feed must be manufactured under a medicated feed mill license utilizing an FDA approved formulation. | |
| NOTE: Coccidiosis may occur when young pasture cattle are co-mingled with adult cattle passing coccidial oocysts. | ||
| Cattle up to 800 lbs | 1 mg lasalocid sodium per 2.2 lbs body weight/day | For control of coccidiosis caused by Eimeria bovis and E. zuernii. Hand feed to provide up to 360 mg lasalocid sodium per head per day. |
| Sheep maintained in confinement | 20-30 grams lasalocid sodium per ton of total ration (90% dry matter) | For prevention of coccidiosis caused by Eimeria ovina, E. crandallis, E. ovinoidalis (E. ninakohlyakimovae), E. parva, and E. intricata: Feed as the sole ration to provide 15 to 70 mg lasalocid sodium per head per day depending on the body weight. |
No withdrawal period is required when used according to labeling.
A withdrawal period has not been established for this product in pre-ruminating calves.
Do not use in calves to be processed for veal.
Not for use in humans. Keep out of reach of children. When mixing and handling lasalocid sodium Type A medicated articles, use protective clothing,
impervious gloves and a dust mask. Avoid contact with eyes. Operators should wash hands thoroughly with soap and water after handling.
Feeding undiluted or mixing errors may result in an excess lasalocid concentration which could be fatal to cattle and sheep. Do not allow horses or other
equines access to Type A articles or Type B feeds containing lasalocid as ingestion may be fatal. Safety of lasalocid for use in unapproved species has not
been established.
Store below 25°C (77°F), excursions permitted to 37°C (99°F).
Restricted drug (California) - Use only as directed. Not for human use.
Approved by FDA under NADA # 096-298
Questions/Comments? For technical assistance or to obtain a Safety Data Sheet(s), contact Phibro Animal Health Corporation at 888-403-0074 or www.pahc.com. To report side
effects, contact Phibro Animal Health Corporation at 1-888-475-7355. For additional information about reporting side effects for animal drugs, contact FDA at 1-888-FDA-VETS or
www.fda.gov/reportanimalae
Phibro, Phibro logo and Bovatec are trademarks owned by or licensed to Phibro Animal Health Corporation or its affiliates.
Distributed by:
Phibro Animal Health Corporation
Teaneck, NJ 07666
176-9036-05
Net Wt 50 LB (22.68 kg)
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 66104-1461-1 | Bovatec | 22.68 kg in 1 BAG | POWDER | 22.68 | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 66104-1461 | 66104-1461-1 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| LASALOCID SODIUM | W2S5C71Y3G | ACTIM |
Adverse event summaries are temporarily unavailable. Other product information remains available.